Hormonal
Tirzepatide significantly increases the risk of gastrointestinal adverse events, including nausea, vomiting, and diarrhea, compared to placebo.
Be prepared for potential stomach issues like nausea, vomiting, and diarrhea when starting tirzepatide. These side effects are common and significantly more likely than with a placebo. Starting at a low dose and increasing slowly can help your body adjust. If side effects are severe, talk to your doctor about adjusting your dose or stopping the medication.
However, the risk of adverse events such as nausea (OR 4.26, 95% CI 2.60 to 3.81), vomiting (OR 8.35, 95% CI 5.19 to 13.45), and diarrhea (OR 3.57, 95% CI 2.80 to 4.57) was significantly higher for tirzepatide versus placebo.
Why this rating
Meta-analysis of RCTs provides robust evidence for safety outcomes.
Source
Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials
Ligang Liu et al. · International Journal of Clinical Pharmacy · 2024
DOI 10.1007/s11096-024-01779-x
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →